Literature DB >> 20814207

Classification of chronic pancreatitis.

Tomica Milosavljevic1, Mirjana Kostic Milosavljevic, Miodrag Krstic, Ivan Jovanovic.   

Abstract

Chronic pancreatitis (CP), defined as a continuing inflammatory disease of the pancreas characterized by irreversible morphological changes which typically cause abdominal pain and/or permanent impairment of pancreatic function, has proved resistant to categorization. The disease may present clinically either with an individual symptom or a combination of symptoms associated with loss of pancreatic function. The single most frequent symptom of CP is pain, either in the form of intermittent episodes or in a more chronic or persistent pattern. The natural history of CP is usually characterized by progression of tissue damage and various degrees of exocrine and endocrine pancreatic insufficiency, which will become apparent over time. The main reason for the lack of guided strategies in the therapeutic management of CP is the absence of a clinically applicable classification of CP. In the past, several classifications have certainly contributed to a better understanding of the pathogenesis and pathophysiology of CP. The meetings in Marseilles (1963 and 1984), Cambridge (1984) and in Rome (1985) added a great deal of information to our knowledge of the pathogenesis and evolution of CP. More recent work on understanding the temporal course of CP led to the Zurich international classification which has been used to define patient cohorts in recent studies of patients undergoing surgery for CP. In order to combine clinical experience in the field of CP with progress in diagnostic methods and new molecular technologies for the assessment of CP, a classification of CP based on key clinical aspects is crucial. A new classification should first be validated to determine whether it can be applied to the majority of patients with CP, and then the value of such a classification needs to be tested in our understanding of the natural course in different etiologies (progression, arrest, regression) and most importantly, to study the clinical outcome when different therapeutic strategies are applied. Copyright (c) 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20814207     DOI: 10.1159/000319409

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  3 in total

1.  Methods of a New Chronic Pancreatitis and Spontaneous Pancreatic Cancer Mouse Model Using Retrograde Pancreatic Duct Injection of Dibutyltin Dichloride.

Authors:  Deyu Zhang; Wanshun Li; Meiqi Wang; Hua Yin; Chuanchao Xia; Keliang Li; Haojie Huang
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

2.  Pathophysiology of chronic pancreatitis induced by dibutyltin dichloride joint ethanol in mice.

Authors:  Hong Zhang; Bin Liu; Xiao-Fan Xu; Ting-Ting Jiang; Xiao-Qin Zhang; Ying-Li Shi; Yu Chen; Fang Liu; Jie Gu; Lin-Jia Zhu; Nan Wu
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

3.  Meandering main pancreatic duct as a relevant factor to the onset of idiopathic recurrent acute pancreatitis.

Authors:  Wataru Gonoi; Hiroyuki Akai; Kazuchika Hagiwara; Masaaki Akahane; Naoto Hayashi; Eriko Maeda; Takeharu Yoshikawa; Shigeru Kiryu; Minoru Tada; Kansei Uno; Hiroshi Ohtsu; Naoki Okura; Kazuhiko Koike; Kuni Ohtomo
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.